ArticleCurrent medicinal chemistry2025
LINC00651, A Long Non-coding RNA, Acts as a Catalyst in the Progression of Breast Cancer by Promoting Proliferation, Migration, and Invasion.
Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe incidence of Breast Cancer (BC), a prevalent malignancy in women, has gone up recently, although the molecular pathways underlying the carcinogenesis of BC are still unknown. Long non-coding RNAs (lncRNAs) have become important tumor progression regulators.
methodsThe present study has revealed increased expression of LINC00651 in BC tissues through a thorough investigation of whole-transcriptome resequencing on matched BC and normal tissues from 8 patients. It is yet unknown precisely as to what biological function LINC00651 serves in BC. To obtain further insight, 39 matched pairs of breast tumors and normal tissues underwent Real-time quantitative Polymerase Chain Reaction (RT-qPCR) for validation. The validated cohort's clinicopathologic characteristics were then carefully examined. Following short interfering RNA transfection, proliferation, colony formation, migration, invasion, and examination of phenotypes associated with the Epithelial-mesenchymal Transition (EMT) were conducted in BC cell lines (MDA-MB-231 and BT-549).
resultsOur findings have confirmed that LINC00651 plays a role in augmenting BC cell lines' proliferation, migration, and invasion. Consequently, LINC00651 can be considered a potential new therapeutic target for BC treatment.
conclusionAs breast cancer remains a significant health concern, understanding its molecular underpinnings is crucial for developing effective treatments. The identification of LINC00651 as a promoter of BC cell growth and metastasis has suggested that it could be a promising target for future therapeutic interventions, potentially offering new avenues for improved patient outcomes.
Indexed as
Identifiers
39171588What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.